Research programme: immunoconjugates - MultiCell Immunotherapeutics/OXIS International

Drug Profile

Research programme: immunoconjugates - MultiCell Immunotherapeutics/OXIS International

Alternative Names: Antibody-drug conjugates - OXIS International

Latest Information Update: 13 Apr 2015

Price : $50

At a glance

  • Originator MultiCell Immunotherapeutics
  • Class Immunoconjugates
  • Mechanism of Action NF-kappa B inhibitors; P38 mitogen-activated protein kinase inhibitors; SQSTM1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer; Multiple myeloma; Osteolysis

Most Recent Events

  • 12 Mar 2015 Early research in Breast cancer, Multiple myeloma and Osteolysis associated with multiple myeloma in USA (Parenteral)
  • 12 Mar 2015 Oxis Biotech licensed rights to OXS 2175 and OXS 4235 to MultiCell Immunotherapeutics to develop Immunocojugates comprising the drugs ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top